8-K: Rivian CEO Scaringe Gets New Performance Award, Salary Hike

Rivian Automotive, Inc. has granted CEO Robert J. Scaringe a new performance-based equity award of up to 36.5 million shares and doubled his base salary to $2 million, replacing a prior award deemed unlikely to vest.

Summary

• Rivian's Compensation Committee cancelled the 2021 CEO Performance Award (20,355,946 shares) and granted a new 2025 CEO Award for up to 36,500,000 shares of Class A Common Stock to CEO Dr. Robert J. Scaringe on November 6, 2025.
• The new award represents a net increase of 16,144,054 shares compared to the cancelled award.
• The 2025 CEO Award is entirely at-risk, requiring achievement of rigorous, challenging, pre-established performance goals over a multi-year period and continued service as CEO.
• Vesting is tied to significant stock price and financial performance improvements, including nearly $153 billion in incremental stockholder value for stock price hurdles ranging from $40 to $140 per share.
• Financial performance goals include achieving various levels of positive adjusted operating income and positive cash flow from operations by December 31, 2032.
• Dr. Scaringe's annual base salary was concurrently increased from $1,000,000 to $2,000,000.
• Dr. Scaringe also received a Profits Interest Award in Mind Robotics, a newly-formed entity, granting up to a 10% economic interest once profits and gains exceed a certain threshold, fully vested on November 6, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a strong commitment to retaining and incentivizing the CEO with a performance-driven compensation package tied to ambitious financial and stock price goals, which could be positive for long-term shareholder value. However, the significant increase in potential dilution and base salary, coupled with the failure of the previous award, introduces some caution.

Positives

• The new 2025 CEO Award is designed to retain and incentivize Dr. Scaringe to execute on the Company's critical next phase, including progressing its technology roadmap and launching R2.
• The award is entirely at-risk and tied to rigorous, challenging performance goals, including significant stock price appreciation (up to $140 per share) and achieving positive adjusted operating income and cash flow from operations.
• Vesting of stock price options would reflect nearly $153 billion in incremental stockholder value, aligning CEO incentives with shareholder returns.
• The Compensation Committee consulted an independent compensation consultant and considered external market data for comparable executives.
• No additional discretionary equity awards are intended for Dr. Scaringe during 2026, providing clarity on future equity compensation.

Negatives

• The new 2025 CEO Award represents a net increase of 16,144,054 shares compared to the cancelled 2021 award, potentially leading to increased shareholder dilution if performance targets are met.
• Dr. Scaringe's annual base salary was doubled from $1,000,000 to $2,000,000, increasing fixed compensation costs.
• The previous 2021 CEO Performance Award was cancelled due to the "unlikeliness of attainment of the associated performance goals," which could raise questions about the initial goal setting or past performance.
• The Profits Interest Award in Mind Robotics, while approved by an independent committee, grants Dr. Scaringe a separate economic interest in a subsidiary, which could introduce complexity.

Risks

• The Company may not achieve the anticipated benefits of the 2025 CEO Award, such as successful CEO retention or the execution of strategic initiatives like the R2 launch.
• The rigorous performance goals, including stock price hurdles up to $140 and achieving positive adjusted operating income and cash flow from operations, may not be met, leading to no value realization for the CEO and potentially indicating underperformance for the Company.
• The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations, as detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The issuance of shares underlying the 2025 CEO Award is subject to termination or expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Future Outlook

The Company's plans and expectations regarding the 2025 CEO Award are to ensure continued CEO retention and incentivization. The award is designed to motivate Dr. Scaringe to execute on the Company's critical next phase, including progressing its technology roadmap and launching the R2 vehicle. The performance goals are set to drive significant stock price and financial performance improvements, specifically achieving positive adjusted operating income and positive cash flow from operations.

Management Comments

• "The 2025 CEO Award is designed to retain and incentivize Dr. Scaringe to execute on the Company's critical next phase as it progresses its technology roadmap and launches R2, which the Committee believes is in the best interests of the Company and its stockholders."
• "The Committee does not intend to grant any additional discretionary equity awards to Dr. Scaringe during 2026."
• The Committee considered "the lack of incentive provided by the 2021 CEO Performance Award due to the unlikeliness of attainment of the associated performance goals."

Industry Context

This compensation package reflects a trend in the high-growth technology and electric vehicle sectors where executive compensation is heavily weighted towards performance-based equity awards to align leadership incentives with long-term shareholder value creation. The cancellation of a prior award due to "unlikeliness of attainment" and the subsequent granting of a new, larger award with revised, albeit still challenging, targets is a common strategy to re-motivate executives and reset expectations in dynamic industries. The focus on launching new products like R2 and achieving profitability metrics (adjusted operating income, cash flow) is critical for EV companies transitioning from growth-at-all-costs to sustainable operations, mirroring broader industry pressures for financial discipline.

Comparison to Industry Standards

• The structure of the 2025 CEO Award, with a significant portion tied to ambitious stock price hurdles (up to $140, representing 820% premium) and financial performance targets (positive adjusted operating income and cash flow from operations), is comparable to "mega-grants" seen in other high-growth tech companies, such as Tesla's 2018 CEO performance award to Elon Musk which also featured extremely aggressive market capitalization and operational milestones.
• The doubling of Dr. Scaringe's base salary from $1 million to $2 million places his fixed compensation in the upper tier for CEOs of publicly traded companies, particularly those in the automotive and technology sectors, though potentially lower than some established auto industry CEOs whose total compensation might be higher due to larger cash bonuses or different equity structures.
• The inclusion of a Profits Interest Award in a newly-formed subsidiary, Mind Robotics, is a less common but emerging practice, potentially mirroring structures seen in private equity or venture-backed ventures, aiming to incentivize leadership in specific, high-potential ventures within a larger corporate structure.
• The Committee's explicit mention of consulting an independent compensation consultant and considering external market data for "similarly situated executives among comparable companies" suggests an effort to benchmark the compensation against industry norms, though the specific comparable companies are not disclosed.

Management Changes

Corporate Governance

Related Party Transactions

• On November 6, 2025, Mind Robotics, LLC, a subsidiary of Mind Robotics, Inc. (a newly-formed entity of the Company), issued 1,000,000 common units (Profits Interest Award) to Dr. Scaringe in connection with his service as Chair of the board of directors of Mind Robotics.
• The Profits Interest Award provides Dr. Scaringe with up to a 10% economic interest in Mind Robotics once its profits and gains exceed a certain threshold.
• This issuance was approved by a special committee of the Board made up of disinterested and independent directors.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation if ambitious performance targets (stock price up to $140, positive adjusted operating income, positive cash flow) are met, aligning CEO incentives. However, there is also potential for increased dilution from the larger share grant and increased fixed compensation costs from the doubled base salary.
• Employees: The CEO's renewed incentive and focus on strategic goals like the R2 launch could provide clearer direction and stability for employees.
• Customers: Successful execution of the technology roadmap and R2 launch, driven by CEO incentives, could lead to innovative products and improved customer offerings.
• Management: The Compensation Committee's decision to replace the prior award due to "unlikeliness of attainment" and set new, challenging goals signals a high-performance expectation for the entire management team.

Next Steps

• The Company will file a copy of the common unit agreement for the Mind Robotics Profits Interest Award with its next Form 10-K.
• The shares underlying the 2025 CEO Award will only be issued upon termination or expiration of the waiting period or periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Dr. Scaringe is expected to execute on the Company's critical next phase, including progressing its technology roadmap and launching R2.

Key Dates

Recommendation

The filing details a significant restructuring of CEO compensation, aiming to strongly incentivize Dr. Scaringe to achieve ambitious long-term goals, including substantial stock price appreciation and financial profitability. While the increased potential dilution and higher base salary are notable, the "entirely at-risk" nature of the award, tied to rigorous performance conditions, aligns the CEO's interests with shareholder value creation. The cancellation of the previous award due to unlikelihood of vesting suggests a pragmatic approach to executive motivation. Given the long-term nature of these incentives and the strategic importance of the R2 launch, a "hold" recommendation is appropriate as the market assesses the feasibility of these ambitious targets and the company's execution capabilities. Investors should monitor progress on the stated financial and operational goals.

Keywords

Rivian, RIVN, CEO compensation, executive compensation, stock options, performance award, Robert J. Scaringe, equity award, adjusted operating income, cash flow from operations, stock price hurdles, corporate governance, electric vehicles, EV manufacturing, R2 launch, Mind Robotics